BiotechTube

Alendronate (Fosamax)

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Juvenile Osteoporosis

Conditions

Juvenile Osteoporosis, Low Bone Density, Fractures

Trial Timeline

Jul 1, 2009 → Oct 1, 2010

NCT ID
NCT00920075

About Alendronate (Fosamax)

Alendronate (Fosamax) is a pre-clinical stage product being developed by Merck for Juvenile Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00920075. Target conditions include Juvenile Osteoporosis, Low Bone Density, Fractures.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00920075Pre-clinicalCompleted

Competing Products

20 competing products in Juvenile Osteoporosis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
69
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
AdalimumabEisaiPhase 3
77
AbataceptOno PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
BaricitinibEli LillyPhase 3
77
Baricitinib + TocilizumabEli LillyPhase 3
77
adalimumab + MethotrexateAbbViePre-clinical
23
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
77
Adalimumab + RisankizumabAbbViePhase 3
77
AdalimumabAbbViePhase 3
77
naproxen + esomeprazoleAstraZenecaPhase 1
33
canakinumabNovartisPhase 3
77
SecukinumabNovartisPhase 1
33
ACZ885 150 mg (Canakinumab)NovartisPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85